Vonafexor is under clinical development by Enyo Pharma and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase II drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vonafexor’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vonafexor overview

EYP-001 (PXL-007) is under development for the treatment of Alport syndrome, autosomal dominant polycystic kidney disease, chronic kidney disease and non-alcoholic steatohepatitis (NASH). The drug candidate is administered through oral route as tablet, capsule and solution. It acts by targeting FXR (farnesoid X) receptor. It was also under development for the treatment of type 2 diabetes and chronic hepatitis B.

Enyo Pharma overview

Enyo Pharma is a biopharmaceutical company that develops molecules modulating host functions for the treatment of acute and chronic viral infections. The company provides technology which develops tools combining biological experimentation and computational development to identify key cellular proteins controlling virus replication. Enyo Pharma constructed a database made up of a library of virus derived peptides for the discovery of new antiviral drugs. The company also carries out hits identification and drug candidate’s identification for viral infections, among others. It collaborations with the Infectiology Center of Lyonbiopole, Jean Merieux BSL-4 Laboratory and other international academic groups. Enyo Pharma is headquartered in Lyon, Rhone Alpes, France.

For a complete picture of Vonafexor’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.